Angus MacLeod, David Della Penta

Jan 12, 2006

Premium

Galapagos said this week that Angus MacLeod has joined the company's service division BioFocus as director of medicinal chemistry.

MacLeod previously worked at Merck Sharp & Dohme, most recently as senior director of medicinal chemistry, Galapagos said.

Fisher Scientific said this week that President and CEO David Della Penta will retire at the end of 2006.

He has been with Fisher since 1998. The company said additional announcements regarding his successor will be made later in the year.

Filed under

Gene Editing, Gene Silencing, & CRISPR

RNAi

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.